Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 132   

Articles published

VRX 159.86 +0.20 (0.13%)
price chart
Valeant Pharmaceutical International Inc. Changes Strategy; Is Now the Time to ...
The strategy for Valeant Pharmaceutical International Inc. (TSX: VRX)(NYSE: VRX) since its inception has been to acquire companies and integrate them into the overall ecosystem of the bigger corporation.
Valeant Pharmaceuticals Intl Sees Significant Decline in Short Interest (VRX)  sleekmoney
Valeant Pharmaceuticals Intl Short Interest Down 29.4% in November (VRX)  Intercooler
Related articles »  
Valeant Pharmaceuticals International Inc to drop deal-making for now to cut ...
NEW YORK/WINNIPEG - Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position ...
Related articles »  
Valeant Pharmaceutical International Inc. Lost its Bid for Allergan, Inc; Now ...
For the past eight months, Valeant Pharmaceutical International Inc. (TSX: VRX)(NYSE: VRX) has been trying to purchase Allergan, Inc. (NYSE: AGN).
Valeant Comments On Allergan Announcement  PR Newswire (press release)
Stymied by Actavis-Allergan deal, Valeant looks for another M&A  The Globe and Mail
Related articles »  
Why Valeant Pharmaceuticals Intl Inc. and Allergan Inc. Would Be Better Together
Valeant Pharmaceuticals Intl Inc.(TSX: VRX)(NYSE: VRX) and Pershing Square Capital Management LP submitted a hostile bid for Allergan Inc. (NYSE: AGN) months ago, but any potential for a deal appeared dead after both sides exchanged barbs.
Allergan Ups Earnings Guidance Amid Takeover Battle With Valeant  Bidness ETC
Allergan, Inc Up As Deutsche Bank Initiates Coverage With Buy Rating  Benzinga
Related articles »  
Making Sense of the Valeant Pharmaceuticals International Inc. and Allergan ...
There's a lot of posturing and name-calling going on between Valeant Pharmaceuticals International Inc. (TSX:VRX)(NYSE:VRX) and Allergan, Inc. (NYSE:AGN).
Most Critical Documents Supporting Allergan, Valeant  ValueWalk
Related articles »  
Valeant Pharmaceuticals Inc moves on after Allergan, Bill Ackman 'speedbump'
In the wake of the Quebec drug giant's failed takeover bid for Allergan Inc., the California-based maker of the face-freezing drug, Valeant's CEO Mike Pearson praised shareholders on a conference call with analysts Thursday for supporting the firm ...
The Acquisition Plans and Business Development Plans of Valeant ...
Valeant's failed Allergan bid may have been more damaging than first thought  The Globe and Mail
Actavis plans new merger approach for Allergan Inc as Valeant Pharmaceuticals ...
Allergan, which has repeatedly rejected offers from Valeant Pharmaceuticals International Inc, would consider a takeover proposal that values the company at above $200 per share, some of these people said.
DEALTALK-Actavis may reap benefits of Valeant's hard work on Allergan  Reuters
Valeant, Pershing Square to Boost Allergan Bid  Wall Street Journal
Related articles »  
What Analysts Think About Valeant Pharmaceuticals Intl Inc's Increased 2015 ...
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) Pharmaceuticals held a conference call with investors on Thursday, January 8th, in which the company increased its guidance for 2015. Initially, Valeant had predicted $9.1 billion in revenue and $10 ...
Valeant Pharmaceuticals Intl Inc (VRX) Releases Q4 Earnings Guidance  WKRB News
Valeant Pharmaceuticals Intl Inc (VRX) Issues FY15 Earnings Guidance  The Legacy
Valeant Pharmaceuticals Intl Inc (VRX): Bausch + Lomb Imaging System ...
Valeant Pharmaceuticals Intl Inc (NYSE:VRX)'s wholly owned subsidiary Bausch + Lomb recently secured U.S. FDA clearance for an advanced Swept Source OCT and updated software for its VICTUS´┐Ż Femtosecond Laser Platform. VICTUS is one of the only ...
Valeants Bausch + Lomb Imaging System Cleared by FDA
Bausch + Lomb Introduces New Optical Software  Drug Discovery & Development
Valeant Announces Launch of Private Offering of Senior Notes
15, 2015 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it has launched an offering of approximately $1.0 billion aggregate principal amount of senior unsecured notes (the "Notes").
Valeant Announces Redemption of All of the Approximately $500 Million ...  PR Newswire (press release)